About Tay-Sachs Disease
Tay-Sachs disease is a fatal genetic disorder caused by mutations in the HEXA gene, resulting in deficiency of the enzyme beta-hexosaminidase A. Without this enzyme, GM2 ganglioside accumulates progressively in nerve cells of the brain and spinal cord, destroying them. The infantile form is the most severe, with neurological deterioration beginning around 3-6 months of age; juvenile and adult-onset forms also exist with slower progression.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Tay-Sachs Disease trials.
Trials often stratify by disease form — specify infantile, juvenile, or adult-onset when searching
Residual hexosaminidase A enzyme activity level is a common baseline eligibility criterion
Gene therapy trials may require no prior substrate reduction therapy (SRT) for a washout period
Carrier status in family members may qualify relatives for natural history studies
Patient Resources
Find recruiting Tay-Sachs Disease trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Tay-Sachs Disease. Updated daily.